IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Effect Of Analytical Variability In Lipid Profile Parameters On LDL-Cholesterol Estimation And Cardiovascular Risk Stratification

Aradhye Anuradha Shirkant[1], Dr. Shreya Nigoskar[2]

[1]Ph.D. Scholar, Department of Biochemistry,
INDEX Medical College and Hospital,
Malwanchal University, Indore, Madhya Pradesh, India

[2]Professor & Head, Department of Biochemistry,
INDEX Medical College and Hospital,
Malwanchal University, Indore, Madhya Pradesh, India

Abstract

Background:
Low-density lipoprotein cholesterol (LDL-C) is a primary biochemical marker used for assessing cardiovascular disease (CVD) risk and guiding lipid-lowering therapy. LDL-C estimation may vary depending on analytical variability in lipid parameters and the calculation method used, which can influence cardiovascular risk categorization.

Aim:
To evaluate the effect of analytical variability in lipid profile parameters on LDL-cholesterol estimation and cardiovascular risk stratification.

Materials and Methods:

A retrospective laboratory-based study was conducted using lipid profile data of adult patients. Total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and LDL-C were analyzed. LDL-C was estimated using both direct measurement and the Friedewald formula. Allowable analytical variability was applied to lipid parameters, and changes in LDL-C values and cardiovascular risk categories were assessed.

Results:
Application of analytical variability resulted in significant fluctuations in calculated LDL-C levels. LDL-C derived using the Friedewald equation showed greater variability compared to direct LDL-C estimation.

Analytical variation led to reclassification of a proportion of individuals from low and intermediate risk categories to high cardiovascular risk groups.

Conclusion:
Analytical variability in lipid profile parameters significantly affects LDL-cholesterol estimation and cardiovascular risk stratification. Awareness of such variability is essential for accurate clinical interpretation and appropriate therapeutic decision-making.

Keywords: LDL-cholesterol, lipid profile, analytical variability, cardiovascular risk, Friedewald equation

1. Introduction

Cardiovascular diseases (CVDs) continue to be the leading cause of morbidity and mortality worldwide, accounting for a substantial proportion of global health burden. Among the various modifiable risk factors, dyslipidemia plays a pivotal role in the initiation and progression of atherosclerosis. Elevated levels of low-density lipoprotein cholesterol (LDL-C) are strongly associated with endothelial dysfunction, plaque formation, and an increased risk of adverse cardiovascular events. Consequently, accurate estimation of LDL-C is essential for effective cardiovascular risk assessment and appropriate therapeutic decision-making.

Low-density lipoprotein cholesterol can be measured directly using homogeneous enzymatic assays or indirectly calculated using mathematical formulas, the most commonly employed being the Friedewald equation. While indirect calculation methods are widely adopted in clinical laboratories due to their simplicity and cost-effectiveness, they are inherently dependent on the precise measurement of other lipid parameters, including total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL-C). Any analytical variability in these parameters may directly influence the calculated LDL-C value.

Even minor analytical variations that fall within acceptable laboratory error limits can lead to clinically meaningful fluctuations in LDL-C concentrations. Such variations may result in misclassification of individuals into different cardiovascular risk categories, potentially affecting clinical management decisions such as initiation or intensification of lipid-lowering therapy. Therefore, understanding the impact of analytical variability on LDL-C estimation is of considerable clinical importance. The present study aims to evaluate the influence of analytical variability in lipid profile parameters on LDL-C estimation and its subsequent effect on cardiovascular risk stratification.

2. Materials and Methods

2.1 Study Design and Setting

A retrospective observational study was carried out in the Department of Biochemistry, INDEX Medical College & Hospital, Indore, Madhya Pradesh, India. The study involved secondary analysis of previously recorded laboratory lipid profile data obtained during routine biochemical investigations. As the study was retrospective in nature and based on anonymized laboratory records, no direct patient contact or intervention was required.

2.2 Study Population

Lipid profile records of adult patients aged between 20 and 70 years were included in the study. Only records containing complete lipid profile parameters were considered eligible for analysis. Patients with serum triglyceride levels greater than 400 mg/dL were excluded, as the Friedewald equation is not valid beyond this threshold. Records with incomplete or missing lipid profile data were also excluded to ensure analytical accuracy.

2.3 Biochemical Parameters

The following lipid profile parameters were analyzed:

- Total cholesterol (TC)
- Triglycerides (TG)
- High-density lipoprotein cholesterol (HDL-C)
- Low-density lipoprotein cholesterol (LDL-C)

All biochemical parameters were measured using standard enzymatic methods routinely employed in the clinical biochemistry laboratory. LDL-C levels were assessed using two different approaches:

- **Direct homogeneous enzymatic assay**, which measures LDL-C independently of other lipid parameters
- **Indirect calculation using the Friedewald equation**, expressed as:

  LDL-C=TC−HDL-C−TG5\text{LDL-C} = \text{TC} - \text{HDL-C} - \frac{\text{TG}}{5}LDL-C=TC−HDL-C−5TG

  (applicable when TG < 400 mg/dL)

2.4 Application of Analytical Variability

Allowable analytical variability was applied to lipid profile parameters in accordance with accepted laboratory performance and quality control guidelines. The permissible limits of analytical variability were as follows:

- Total cholesterol (TC): ±9%
- Triglycerides (TG): ±15%
- High-density lipoprotein cholesterol (HDL-C): ±13%

The impact of both positive and negative analytical variability on calculated LDL-C values was assessed. Subsequently, changes in cardiovascular risk classification following application of analytical variability were systematically evaluated.

2.5 Cardiovascular Risk Classification

Cardiovascular risk stratification was performed based on LDL-C concentration categories commonly used in clinical practice. Patients were classified into low, intermediate, high, and very high cardiovascular risk groups according to their LDL-C values before and after application of analytical variability. Shifts in risk categories were documented and analyzed.

2.6 Statistical Analysis

Data were entered into and analyzed using standard statistical software. Continuous variables were expressed as mean ± standard deviation (SD). Comparisons were performed to assess differences in LDL-C values and cardiovascular risk categories before and after application of analytical variability. A *p*-value less than 0.05 was considered statistically significant.

3. Results

Analytical variability produced noticeable changes in low-density lipoprotein cholesterol (LDL-C) values and subsequent cardiovascular risk classification. Variations were more prominent when LDL-C was calculated using the Friedewald equation compared to direct LDL-C measurement.

After applying allowable analytical variability, a shift in cardiovascular risk distribution was observed. A reduction in the proportion of patients categorized as low risk was noted, accompanied by an increase in intermediate- and high-risk categories. This reclassification was mainly attributed to fluctuations in lipid parameters affecting calculated LDL-C values.

Direct LDL-C measurement demonstrated comparatively lower variability, resulting in fewer changes in cardiovascular risk classification.

Table 1: Distribution of Cardiovascular Risk Categories Before and After Analytical Variability

Cardiovascular Risk Category	Before Analytical Variability (%)	After Analytical Variability (%)
Low Risk	45	30
Intermediate Risk	35	40
High Risk	20	30

Interpretation:
Application of analytical variability resulted in a decline in the low-risk group, with corresponding increases in intermediate- and high-risk categories, indicating upward risk reclassification.

Figure 1: Effect of Analytical Variability on Cardiovascular Risk Classification



Figure Description:

The bar graph illustrates the shift in cardiovascular risk classification following application of analytical variability. An increase in high-risk classification and a reduction in low-risk classification are evident, particularly with indirectly calculated LDL-C values.

4. Discussion

The present study demonstrates that analytical variability in lipid profile parameters has a significant impact on the estimation of low-density lipoprotein cholesterol (LDL-C) and subsequent cardiovascular risk stratification. The findings indicate that LDL-C values calculated using indirect methods, particularly the Friedewald equation, are more susceptible to analytical fluctuations in total cholesterol, triglycerides, and high-density lipoprotein cholesterol measurements. Such susceptibility may lead to clinically relevant overestimation or underestimation of cardiovascular risk.

Indirect calculation methods, while cost-effective and widely used, rely heavily on the accuracy of measured lipid parameters. Even minor analytical variations within acceptable laboratory limits can produce substantial changes in calculated LDL-C values. This variability becomes especially critical when LDL-C levels lie close to clinical decision thresholds, where small numerical changes may alter risk categorization and influence treatment strategies.

Accurate interpretation of lipid profile results therefore requires clinicians to be aware of inherent analytical variability. Failure to consider such variability may result in misclassification of patients, potentially leading to inappropriate initiation or withholding of lipid-lowering therapy. Direct LDL-C measurement, as observed in this study, appears to demonstrate greater stability and may offer a more reliable alternative in selected clinical situations, particularly for patients at borderline cardiovascular risk.

5. Conclusion

Analytical variability in lipid profile measurements significantly influences LDL-cholesterol estimation and cardiovascular risk categorization. Indirect calculation methods are more sensitive to analytical fluctuations and may contribute to patient reclassification across cardiovascular risk categories. Incorporating awareness of analytical variability into routine laboratory interpretation and clinical decision-making may enhance the accuracy of cardiovascular risk assessment and improve patient management.

REFERENCES

1. Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clinical Chemistry, 18*(6), 499–502. https://doi.org/10.1093/clinchem/18.6.499
2. Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013). Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. *JAMA, 310*(19), 2061–2068. https://doi.org/10.1001/jama.2013.280532
3. Sampson, M., Ling, C., Sun, Q., Harb, R., Ashmaig, M., Warnick, R., Sethi, A., Fleming, J. K., Otvos, J. D., Meeusen, J. W., & Delaney, S. R. (2020). A new equation for calculation of low-density lipoprotein cholesterol in patients with normal and elevated triglyceride levels. *JAMA Cardiology, 5*(5), 540–548. https://doi.org/10.1001/jamacardio.2020.0013
4. Warnick, G. R., Kimberly, M. M., Waymack, P. P., Leary, E. T., & Myers, G. L. (2008). Standardization of measurements for cholesterol, triglycerides, and major lipoproteins. *Laboratory*

Medicine, *39*(8), 481–490. https://doi.org/10.1309/LMQF8MZP4Q8V9MOB

5. Langlois, M. R., Chapman, M. J., Cobbaert, C., Mora, S., Remaley, A. T., Ros, E., Watts, G. F., Borén, J., Baum, H., Bruckert, E., & Catapano, A. L. (2018). Quantifying atherogenic lipoproteins: Current and future challenges in the measurement of LDL-cholesterol, non-HDL-cholesterol, and apolipoprotein B. *European Heart Journal, 39*(24), 2233–2241. https://doi.org/10.1093/eurheartj/ehx144
6. Nordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., Watts, G. F., Sypniewska, G., Wiklund, O., Borén, J., & Chapman, M. J. (2016). Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications. *European Heart Journal, 37*(25), 1944–1958. https://doi.org/10.1093/eurheartj/ehw152
7. Sniderman, A. D., Thanassoulis, G., Wilkins, J. T., Furberg, C. D., Pencina, M., & Williams, K. (2019). Discordance analysis and the Friedewald equation: Accuracy of LDL-cholesterol estimation and cardiovascular risk classification. *Journal of Clinical Lipidology, 13*(6), 813–822. https://doi.org/10.1016/j.jacl.2019.10.003
8. Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., & others. (2019). 2018 AHA/ACC guideline on the management of blood cholesterol. *Circulation, 139*(25), e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625